Original article
Mysterious Data Policy >> In the social sciences, the inadequate coronavirus data policy of the Robert Koch Institute (RKI) and its focus on the daily or cumulative number of confirmed COVID-19 cases were criticized, albeit only sporadically, as early as spring 2020. For example, one of Germany's leading sociologists, Rainer Schnell—together with Menno Smid of the Infas Institute […]
02.08.2023
Comment from Dr. PH Andrej Rasch, Senior Manager Benefit Assessment/HTA Coordination, Association of Research-Based Drug Manufacturers (e. V.). Topic: current BSG ruling and its consequences.
02.08.2023
The AMNOG procedure has been legally adjusted several times in recent years. A significant change recently occurred with the GKV Financial Stabilization Act (GKV-FinStG), which was passed at the end of 2022. The legal package of measures includes, among other things, new requirements for reimbursement amount negotiations, which change the basic principle of AMNOG. According to these new requirements (so-called “guardrails”), in certain cases a new drug may not cost more than the comparative therapy despite the proven additional benefit. If there is no proven additional benefit, the costs must even be lower. The details of these new requirements are subjected to a critical analysis below.
02.08.2023
A large proportion of people use the Internet to obtain health information. There are also numerous digital information offerings on preventive care documents, which are an important way to plan ahead for illness and treatment situations. As part of a cross-sectional survey on pension documents in the Würzburg region, 240 people were asked about their search for information on the Internet and their experiences in the area of pension documents. The majority of respondents (67%) have already searched for information about pension documents on the Internet.
02.08.2023
With the introduction of the Swiss per-case flat rate system (SwissDRG) in 2012 to contain costs in the healthcare system, a paradigm shift in the billing of healthcare services took place - away from cost recovery towards service financing. In order to cushion the negative effects of the introduction, the legislature included various measures in the Federal Health Insurance Act (KVG). One of these protective measures was acute and transitional care (AÜP). However, the intended benefits of AÜP were not achieved for various reasons. Therefore, the “At Home Instead of Home” project sought to develop a business development model as a possible solution.
02.08.2023
The aim of the present study was to determine the age of new cancer patients in 2010 and 2022 and to evaluate the changes in the proportion of early-onset cancers in the total number of cancer cases in private practices. This retrospective cross-sectional study included adult patients (≥18 years) with an initial cancer diagnosis in 557 private practices in Germany in 2010 or 2022 from the Disease Analyzer database (IQVIA).
02.08.2023
The aim of this analysis was to identify federal state differences in the use of complex acute pain treatment. Hospital case numbers for complex acute pain treatment and all hospital cases in 2021 were taken from the InEK database. These were used to calculate age-standardized rates (ASR) for complex acute pain treatment per 100,000 hospital cases as well as standardized rate ratios (SRR) and 95% confidence intervals (95% CI).
02.08.2023
„"Hospital reforms are always evolutionary processes." Prof. Dr. Jonas Schreyögg, Professor of Health Care Management at the University of Hamburg and a member of the German Council of Experts on the Assessment of Developments in the Health Care System, is considered one of the most influential economists in Germany. In an interview with "Monitor Versorgungsforschung," he has high hopes for the upcoming hospital reform, which he describes as an evolutionary step [...]
05.06.2023
Report on the “constitutional conformity of the reform of hospital planning”
05.06.2023
While the first two events of the MVF specialist congress series “Vaccination Status” in 2021 and 2022 focused more on the medical perspective, this year the thematic cycle was expanded to include that of the scientific community and pharmacists. The first experiences from two innovation fund projects on the subject of vaccination were highlighted and a project was presented that was carried out in cooperation between a private health insurance company and a pharmacists' association.